Fluphenazine decanoate

Research use only, not for human use.

Fluphenazine decanoate is dopamine D2 receptor blockeand is a long-acting phenothiazine neuroleptic that used to treat schizophrenia.

Fluphenazine decanoate is dopamine D2 receptor blockeand is a long-acting phenothiazine neuroleptic that used to treat schizophrenia.(In Vivo):Fluphenazine decanoate (0.22 mg/kg and followed by 0.33 mg/kg; i.m.; 8 times every 3 weeks), as an antipsychotic, increases sensitivity to dopamine on monkey model following extended treatment.Fluphenazine decanoate (25 mg/kg; i.m.; 6 times every 3 weeks; 24 weeks) induces mouth movements in the rat, serves as a pharmacological model of human tardive dyskinesia.Fluphenazine decanoate (1, 2, 3 mg/kg/d; s.c.; 60 d) shows antifertility effects and induces hyperprolactinemia concomitant with gonadotropin suppression in adult male rat.

Fluphenazine decanoate shows activity against T. gondii in human fibroblast cell cultures with an IC50 value of 1.7 mM.

Fluphenazine decanoate (0.22 mg/kg and followed by 0.33 mg/kg; i.m.; 8 times every 3 weeks), as an antipsychotic, increases sensitivity to dopamine on monkey model following extended treatment.Fluphenazine decanoate (25 mg/kg; i.m.; 6 times every 3 weeks; 24 weeks) induces mouth movements in the rat, serves as a pharmacological model of human tardive dyskinesia.Fluphenazine decanoate (1, 2, 3 mg/kg/d; s.c.; 60 d) shows antifertility effects and induces hyperprolactinemia concomitant with gonadotropin suppression in adult male rat. Animal Model:Cebus apella monkey Dosage:0.22 mg/kg and followed by 0.33 mg/kg Administration:Intramuscular injection; 8 times per 3 weeks; 0.22 mg/kg for 63 weeks and 0.33 mg/kg for 6 weeksResult:Decreased the aggressiveness composite behavioral variables (CBV). Resulted stereotypic behavior induced by agonist and decreased prolactin response to AMPH.Animal Model:Male Sprague-Dawley rats (250 g)Dosage:25 mg/kg Administration:Intramuscular injection into the hind limb; 24 weeks Result:Resulted in spontaneous vacuous chewing mouth movements and jaw tremor.Animal Model:Adult male rats Dosage:1, 2, 3 mg/kg/d Administration:Subcutaneous injection between 10:00-12:00 h; 60 daysResult:Increased serum prolactin level and suppressed serum LH and FSH levels at day 60.Increased hypothalamic tyrosine hydroxylase levels, enhanced chromatin decondensation, and resulted DNA denaturation.

——

GPCR/G Protein

Dopamine Receptor

D2

Others

Psoriasis

5002-47-1

591.77

C32H44F3N3O2S

>98% (HPLC)

DMSO:125 mg/mL (211.23 mM; Need ultrasonic)

CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

2-[4-[3-[2-(Trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethyl decanoate

(-20℃)

With Ice Pack

≥ 2 years